Lexaria Bioscience

LEXX

Market cap $15.1M

More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update. On June 7th, Novo Nordisk® ("Novo") announced that over three million Wegovy® pill prescriptions had been filled since its initial launch on January 5, 2026, in what they call "one of the strongest US pharmaceutical launches by volume on record".

More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as treatable with GLP-1 drugs

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™   Kelowna, British Columbia - June 9 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 (“GLP-1”) drugs (the “Study”) to explore the potential for improved DehydraTECH TM performance as well as potentially stake new intellectual property claims.

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs (the "Study") to explore the potential for improved DehydraTECHTM performance as well as potentially stake new intellectual property claims. Retatrutide is one of Eli Lilly and Company's® leading next-generation GLP-1 drugs undergoing extensive trials in the weight loss space, where two current Phase 3 studies were recently reported to deliver average weight loss of 28.3% - or 70 pounds - when evaluating patients who stayed on the drug.

Kelowna, British Columbia - June 3 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces that it is attending the BIO International Convention (“BIO”) from June 22-25 in San Diego, CA . Lexaria's attendance at last year's 2025 BIO convention served as a catalyst for its greatly expanded business development (“BD”) program that is now starting to deliver positive results and which Lexaria intends to build upon at this year's BIO conference.   “We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”

CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities   Kelowna, British Columbia – May 7, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today released the second episode of Reformulated: Into the Mainstream , the Company's ongoing investor communications series.

Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today announced the launch of Reformulated: Into the Mainstream, an ongoing investor communications series designed to support transparency, consistent engagement, and alignment with shareholders and the broader investment community. As Lexaria continues executing its strategy within the rapidly evolving GLP-1 and oral drug delivery landscape, the video series will feature regular interviews and management discussions with Lexaria leadership.

KELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH™ technology in a pre-clinical setting. The original agreement has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026 research & development ("R&D") results related to GLP-1.

Contracts signed for Animal Study #2: GLP-1-A26-2 Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 Animal Study #2 (GLP-1-A26-2) that will evaluate a number of formulation enhancements with two next-generation glucagon-like peptide-1 ("GLP-1") drugs in animals (the "Study") to explore the potential for improved DehydraTECH performance as well as potentially stake new intellectual property claims. Contracts with the CRO have been signed; Study design has been completed; formulation manufacturing is underway; and dosing is expected to begin within 30 days.

Contracts signed for Animal Study #2:  GLP-1-A26-2  Amycretin and retatrutide to be tested for compatibility with DehydraTECH